SCHEMBL26255335

SCHEMBL26255335

CCc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(O)[C@@H]1F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 5/20 0.57
▸ ADORA3 P0DMS8 3/20 0.57
▸ ADORA2A P29274 2/20 0.57
▸ ADORA1 P30542 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ DPP4 P27487 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ SLC28A1 O00337 1/20 0.57
▸ MAP3K7 O43318 1/20 0.57
▸ SLC28A2 O43868 1/20 0.57
▸ GAPDH P04406 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ ADORA2B P29275 1/20 0.57
▸ STAT6 P42226 1/20 0.57
▸ PI4KA P42356 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ PI4K2B Q8TCG2 1/20 0.57
▸ DOT1L Q8TEK3 1/20 0.57
▸ PI4K2A Q9BTU6 1/20 0.57
▸ SLC28A3 Q9HAS3 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22459089 0.91 SLC29A1 (0.55) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL21562412 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL14853873 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL1061428 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL8629179 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL21562155 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL21730121 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL30018675 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL1061425 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL20857243 0.87 SLC29A1 (0.60) SLC29A1ADORA3ADORA2AADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287032-A1 SYNTHESIS OF FLUORINATED NUCLEOTIDES MERCK SHARP & DOHME LLC (US) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287032-A1 SYNTHESIS OF FLUORINATED NUCLEOTIDES NUDT1, NT5C3B, DUT SLC29A1 171/4885ADORA3 81/4885ADORA2A 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback